Compare Supplements

Prescription-only, clinician-directed. Subcutaneous 20 µg once daily within the hour before the first meal of the day, after a 10 µg starting dose for 14 days. DO NOT self-dose.

Morning

Subcutaneous once-daily injection (Adlyxin / Lyxumia)

Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)

Any time

Once-weekly subcutaneous injection (Mounjaro / Zepbound)

• Personal or family history of medullary thyroid carcinoma (MTC) — GLP-1 class C-cell tumor warning
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Prior serious hypersensitivity to lixisenatide or any GLP-1 receptor agonist

• Insulin and sulfonylureas
• Oral medications (general)
• Other GLP-1 receptor agonists

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• History of pancreatitis (use with caution / avoid)

• Oral contraceptives
• Insulin and sulfonylureas
• Oral medications generally